Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
Dyve Biosciences Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 5 distinct examiners and 5 distinct art units. BABSON, NICOLE PLOURDE is the busiest examiner, with 1 pending matter.
The pending work is distributed across five examination channels. This structure may produce different treatments of biological, pharmaceutical, formulation, or therapeutic limitations. Counsel should therefore use application-specific prosecution analysis while keeping shared scientific terminology and disclosure positions consistent.
No examiner is shown as handling more than the stated 1 pending matter. A coordinated review can organize common technical evidence and identify recurring claim issues, but each response should remain tied to the cited references and reasoning in its own action.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BABSON, NICOLE PLOURDE | 1 | 46.5% | +33.9% |
| SONG, JIANFENG | 1 | 56.4% | +32.8% |
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
| KETCHAM, KAREN A | 1 | 21.1% | +39.9% |
| BARBER, KIMBERLY | 1 | 71.1% | +21.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18796818 | FORMULATIONS FOR TRANSDERMAL ADMINISTRATION OF ACTIVE AGENTS | BABSON, NICOLE PLOURDE | — |
| 17817774 | TOPICAL DELIVERY OF BUFFERING AGENTS FOR PREVENTION AND TREATMENT OF VIRAL INFECTIONS | KETCHAM, KAREN A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17830236 | TRANSDERMAL PENETRATION BY MODULATING EPITHELIAL JUNCTIONS | BARBER, KIMBERLY | 73d overdue |
| 18351192 | TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS | MOU, LIYUAN | 49d overdue |
| 18796818 | FORMULATIONS FOR TRANSDERMAL ADMINISTRATION OF ACTIVE AGENTS | BABSON, NICOLE PLOURDE | — |
| 18782470 | TRANSDERMAL CARRIER | SONG, JIANFENG | — |
| 17817774 | TOPICAL DELIVERY OF BUFFERING AGENTS FOR PREVENTION AND TREATMENT OF VIRAL INFECTIONS | KETCHAM, KAREN A | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| 1613 | 1 |
| 1628 | 1 |
| 1614 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18796818 | FORMULATIONS FOR TRANSDERMAL ADMINISTRATION OF ACTIVE AGENTS | BABSON, NICOLE PLOURDE | 1619 | §102§103§112Other | Non-Final OA | — | Pending | Aug 07, 2024 |
| 18782470 | TRANSDERMAL CARRIER | SONG, JIANFENG | 1613 | §103Other | Non-Final OA | — | Pending | Jul 24, 2024 |
| 18351192 | TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS | MOU, LIYUAN | 1628 | §102§103§112DP | Final Rejection | 49d overdue | Pending | Jul 12, 2023 |
| 17817774 | TOPICAL DELIVERY OF BUFFERING AGENTS FOR PREVENTION AND TREATMENT OF VIRAL INFECTIONS | KETCHAM, KAREN A | 1614 | §102§103§112 | Final Rejection | — | Pending | Aug 05, 2022 |
| 17830236 | TRANSDERMAL PENETRATION BY MODULATING EPITHELIAL JUNCTIONS | BARBER, KIMBERLY | 1615 | §103 | Final Rejection | 73d overdue | Pending | Jun 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDyve Biosciences Inc. has 5 pending office actions as of November 2026, spread across 5 art units and 5 examiners.
Nicole Plourde Babson has the most, with 1 of Dyve Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.